AIM Vaccine Co., Ltd. (HKG:6660)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.100
+0.030 (0.98%)
Feb 13, 2026, 3:31 PM HKT
Market Cap3.77B -38.9%
Revenue (ttm)1.38B +6.6%
Net Income-294.87M
EPS-0.25
Shares Out1.23B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume347,200
Average Volume725,830
Open3.110
Previous Close3.070
Day's Range3.070 - 3.140
52-Week Range3.000 - 6.550
Beta0.11
RSI35.22
Earnings DateMar 27, 2026

About AIM Vaccine

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infecti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 1,493
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6660
Full Company Profile

Financial Performance

In 2024, AIM Vaccine's revenue was 1.29 billion, an increase of 8.22% compared to the previous year's 1.19 billion. Losses were -277.23 million, -78.69% less than in 2023.

Financial numbers in CNY Financial Statements